TNDM•benzinga•
Tandem Diabetes Announces NEJM Publication Of Control-IQ+ Trial For Type 2 Diabetes, Showing Significant A1C Reductions Of 0.9% Overall And 2.3% For A1C ≥9%, Meeting Primary Endpoint
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on March 19, 2025 by benzinga